Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BP2202
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : BrightPath Biotherapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
BrightPath, Cellistic Collaborate on BCMA CAR-iNKT Cell Phase 1 Trial
Details : The collaboration aims to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials.
Product Name : BP2202
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 13, 2024
Lead Product(s) : BP2202
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : BrightPath Biotherapeutics
Deal Size : Undisclosed
Deal Type : Collaboration